{"id":2803,"date":"2024-12-20T13:33:00","date_gmt":"2024-12-20T12:33:00","guid":{"rendered":"https:\/\/prueba.esclerosismultiplegalicia.org\/?p=2803"},"modified":"2025-09-09T13:31:36","modified_gmt":"2025-09-09T11:31:36","slug":"briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple","status":"publish","type":"post","link":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/","title":{"rendered":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple"},"content":{"rendered":"\n<h3 class=\"wp-block-heading has-theme-palette-2-color has-text-color has-link-color wp-elements-8032de8b5dd1cedefc3a8b651c908c6d\"><em>&#8220;Esta opci\u00f3n terap\u00e9utica est\u00e1 indicada para o tratamento de pacientes adultos con formas recorrentes de Esclerose M\u00faltiple (EMR) con enfermidade activa definida por caracter\u00edsticas cl\u00ednicas ou de imaxe&#8221;, segundo Esclerosis M\u00faltiple Espa\u00f1a.<\/em><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">O panorama terap\u00e9utico para a&nbsp;<a href=\"https:\/\/esclerosismultiplegalicia.org\/esclerose_multiple_recorrente_remitente_ga.html\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Esclerose M\u00faltiple Recorrente (EMR)<\/strong><\/a>&nbsp;avanzou coa chegada de&nbsp;<strong>Briumvi\u00ae (ublituximab)<\/strong>, un medicamento dese\u00f1ado para tratar a adultos\/as con formas recorrentes desta enfermidade. Este novo tratamento, lanzado en Espa\u00f1a por Neuraxpharm Pharmaceuticals en outubro de 2024, ofrece unha nova opci\u00f3n para quen vive con EMR.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Que \u00e9 Briumvi e como funciona?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Briumvi<\/strong>&nbsp;est\u00e1 indicado para persoas con EMR activa, caracterizada por brotes seguidos de periodos de remisi\u00f3n parcial ou total. O seu compo\u00f1ente principal,&nbsp;<strong>ublituximab<\/strong>, \u00e9 un anticorpo monoclonal que act\u00faa especificamente sobre o&nbsp;<strong>CD20<\/strong>, unha prote\u00edna nos linfocitos B, c\u00e9lulas clave na patox\u00e9nese da&nbsp;<a href=\"https:\/\/esclerosismultiplegalicia.org\/esclerose_multiple_ga.html\" target=\"_blank\" rel=\"noreferrer noopener\">Esclerose M\u00faltiple (EM)<\/a>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Como funciona<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Destruci\u00f3n selectiva de linfocitos B:<\/strong>\u00a0Briumvi provoca a lise destas c\u00e9lulas mediante citotoxicidade celular dependente de anticorpos (CCDA) e do complemento (CDC).<\/li>\n\n\n\n<li><strong>Reduci\u00f3n sostida de linfocitos B:<\/strong>\u00a0en 24 horas, reduce o 96,2% dos linfocitos B, mantendo unha reduci\u00f3n do 97,6% \u00e1s 96 semanas.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Administraci\u00f3n e doses<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Briumvi admin\u00edstrase mediante infusi\u00f3n intravenosa de 1 hora:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Dose inicial:<\/strong>\u00a0d\u00faas infusi\u00f3ns separadas por d\u00faas semanas.<\/li>\n\n\n\n<li><strong>Mantemento:<\/strong>\u00a0unha infusi\u00f3n cada 24 semanas.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Resultados cl\u00ednicos e seguridade<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Os ensaios cl\u00ednicos demostraron:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eficacia na reduci\u00f3n dos brotes.<\/strong><\/li>\n\n\n\n<li><strong>Ralentizaci\u00f3n da progresi\u00f3n da discapacidade.<\/strong><\/li>\n\n\n\n<li>Seguridade comprobada en estudos cl\u00ednicos.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Efectos adversos m\u00e1is com\u00fans<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reaci\u00f3ns relacionadas coa infusi\u00f3n: febre, calafr\u00edos, s\u00edntomas gripais.<\/li>\n\n\n\n<li>Infecci\u00f3ns do tracto respiratorio superior.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A aprobaci\u00f3n de Briumvi<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A&nbsp;<a href=\"https:\/\/www.fda.gov\/about-fda\/fda-en-espanol\" target=\"_blank\" rel=\"noreferrer noopener\">Administraci\u00f3n de Alimentos e Medicamentos (FDA)<\/a>&nbsp;aprobou este tratamento en decembro de 2022 e a&nbsp;<strong>Comisi\u00f3n Europea<\/strong>&nbsp;deu luz verde a mediados de 2023. A chegada de Briumvi a Espa\u00f1a en 2024 marca un avance nas opci\u00f3ns terap\u00e9uticas para as persoas con EMR.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>M\u00e1is informaci\u00f3n<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Para profundizar nos detalles sobre Briumvi, consulta:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2024\/IPT-272-Briumvi-ublituximab.pdf\"><strong>Informe de Posicionamento Terap\u00e9utico (AEMPS)<\/strong><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1231730001\/FT_1231730001.html.pdf\"><strong>Ficha t\u00e9cnica de Briumvi<\/strong><\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/esclerosismultiple.com\/briumvi-nuevo-tratamiento-para-formas-recurrentes-la-esclerosis-multiple\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Podes ler a nova enteira en Esclerosis M\u00faltiple Espa\u00f1a.<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Esta opci\u00f3n terap\u00e9utica est\u00e1 indicada para o tratamento de pacientes&hellip; <a class=\"continue\" href=\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\">Ler m\u00e1is sobre<span> Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"footnotes":""},"categories":[103],"tags":[102,101],"class_list":["post-2803","post","type-post","status-publish","format-standard","hentry","category-novas","tag-investigacion","tag-tratamentos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\" \/>\n<meta property=\"og:locale\" content=\"gl_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM\" \/>\n<meta property=\"og:description\" content=\"&#8220;Esta opci\u00f3n terap\u00e9utica est\u00e1 indicada para o tratamento de pacientes&hellip; Ler m\u00e1is sobre Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple\" \/>\n<meta property=\"og:url\" content=\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\" \/>\n<meta property=\"og:site_name\" content=\"FEGADEM\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T12:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-09T11:31:36+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@fegadem\" \/>\n<meta name=\"twitter:site\" content=\"@fegadem\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4\"},\"headline\":\"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple\",\"datePublished\":\"2024-12-20T12:33:00+00:00\",\"dateModified\":\"2025-09-09T11:31:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\"},\"wordCount\":387,\"publisher\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\"},\"keywords\":[\"Investigaci\u00f3n\",\"Tratamentos\"],\"articleSection\":[\"Novas\"],\"inLanguage\":\"gl-ES\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\",\"name\":\"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM\",\"isPartOf\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#website\"},\"datePublished\":\"2024-12-20T12:33:00+00:00\",\"dateModified\":\"2025-09-09T11:31:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#breadcrumb\"},\"inLanguage\":\"gl-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\/\/esclerosismultiplegalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#website\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/\",\"name\":\"FEGADEM\",\"description\":\"Traballamos mellorando a calidade de vida das persoas con Esclerose M\u00faltiple en Galicia.\",\"publisher\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/esclerosismultiplegalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"gl-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\",\"name\":\"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"gl-ES\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png\",\"contentUrl\":\"https:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png\",\"width\":2558,\"height\":1138,\"caption\":\"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)\"},\"image\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES\",\"https:\/\/x.com\/fegadem\",\"https:\/\/www.instagram.com\/esclerosemultiplegal\/\",\"https:\/\/www.youtube.com\/@fegademfederaciongalegadee3374\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"gl-ES\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/prueba.esclerosismultiplegalicia.org\"],\"url\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/","og_locale":"gl_ES","og_type":"article","og_title":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM","og_description":"&#8220;Esta opci\u00f3n terap\u00e9utica est\u00e1 indicada para o tratamento de pacientes&hellip; Ler m\u00e1is sobre Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple","og_url":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/","og_site_name":"FEGADEM","article_publisher":"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES","article_published_time":"2024-12-20T12:33:00+00:00","article_modified_time":"2025-09-09T11:31:36+00:00","author":"admin","twitter_card":"summary_large_image","twitter_creator":"@fegadem","twitter_site":"@fegadem","twitter_misc":{"Escrito por":"admin","Tempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#article","isPartOf":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/"},"author":{"name":"admin","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4"},"headline":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple","datePublished":"2024-12-20T12:33:00+00:00","dateModified":"2025-09-09T11:31:36+00:00","mainEntityOfPage":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/"},"wordCount":387,"publisher":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#organization"},"keywords":["Investigaci\u00f3n","Tratamentos"],"articleSection":["Novas"],"inLanguage":"gl-ES"},{"@type":"WebPage","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/","url":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/","name":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple - FEGADEM","isPartOf":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#website"},"datePublished":"2024-12-20T12:33:00+00:00","dateModified":"2025-09-09T11:31:36+00:00","breadcrumb":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#breadcrumb"},"inLanguage":"gl-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/12\/20\/briumvi-un-novo-tratamento-para-as-formas-recorrentes-da-esclerose-multiple\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/esclerosismultiplegalicia.org\/"},{"@type":"ListItem","position":2,"name":"Briumvi: un novo tratamento para as formas recorrentes da Esclerose M\u00faltiple"}]},{"@type":"WebSite","@id":"https:\/\/esclerosismultiplegalicia.org\/#website","url":"https:\/\/esclerosismultiplegalicia.org\/","name":"FEGADEM","description":"Traballamos mellorando a calidade de vida das persoas con Esclerose M\u00faltiple en Galicia.","publisher":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/esclerosismultiplegalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"gl-ES"},{"@type":"Organization","@id":"https:\/\/esclerosismultiplegalicia.org\/#organization","name":"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)","url":"https:\/\/esclerosismultiplegalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"gl-ES","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png","contentUrl":"https:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png","width":2558,"height":1138,"caption":"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)"},"image":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES","https:\/\/x.com\/fegadem","https:\/\/www.instagram.com\/esclerosemultiplegal\/","https:\/\/www.youtube.com\/@fegademfederaciongalegadee3374"]},{"@type":"Person","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4","name":"admin","image":{"@type":"ImageObject","inLanguage":"gl-ES","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/prueba.esclerosismultiplegalicia.org"],"url":"https:\/\/esclerosismultiplegalicia.org\/index.php\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/comments?post=2803"}],"version-history":[{"count":1,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2803\/revisions"}],"predecessor-version":[{"id":2804,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2803\/revisions\/2804"}],"wp:attachment":[{"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/media?parent=2803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/categories?post=2803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/tags?post=2803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}